# A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors

> **NCT05205109** · PHASE1 · RECRUITING · sponsor: **Antengene Therapeutics Limited** · enrollment: 98 (estimated)

## Conditions studied

- Locally Advanced or Metastatic Solid Tumors

## Interventions

- **DRUG:** ATG-037
- **DRUG:** KEYTRUDA ®( Pembrolizumab)

## Key facts

- **NCT ID:** NCT05205109
- **Lead sponsor:** Antengene Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-07
- **Primary completion:** 2027-08-30
- **Final completion:** 2028-02-28
- **Target enrollment:** 98 (ESTIMATED)
- **Last updated:** 2025-06-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05205109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05205109, "A Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ATG 037 Monotherapy and Combination Therapy With Pembrolizumab in Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05205109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*